Compare GSK plc (GSK) vs Seagate Technology Holdings PLC (STX) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Seagate Technology (STX) trades at $878.31, up 2.05% with strong recent earnings beats and bullish analyst sentiment. The stock shows robust fundamentals with 21.6% net margins and 96.27% ROE, though valuation metrics appear elevated with P/E at 78.59. Technical indicators are neutral overall with support at $866 and resistance at $893, while the company benefits from AI-driven storage demand and positive industry outlook.

Outlook remains positive with 54.9% analyst buy ratings and $987.86 consensus target, representing 12.5% upside. Key risks include high debt levels (73.31% debt-to-asset ratio) and competitive pressures in the memory sector. The upcoming Q2 earnings report on July 28, 2026, with expected EPS of $5.10, will be critical for near-term direction.